Difluoromethylthioacetic acid | CAS:83494-32-0

We serve Difluoromethylthioacetic acid CAS:83494-32-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Difluoromethylthioacetic acid

Chemical Name:Difluoromethylthioacetic acid
CAS.NO:83494-32-0
Synonyms:DIFLUOROMETHYLTHIO ACETIC ACID
DIFLUOROMETHYLSULFANYL-ACETIC ACID
Molecular Formula:C3H4F2O2S
Molecular Weight:142.12400
 
Physical and Chemical Properties:
Density:1.255
Boiling point:126.2ºC
Flash point:30.1ºC
Index of Refraction:1.396
 
Specification:
Appearance:Off-white to white crystalline powder
Purity:≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:An intermediate of Flomoxef
 



Contact us for information like Difluoromethylthioacetic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,DIFLUOROMETHYLSULFANYL-ACETIC ACID physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,DIFLUOROMETHYLTHIO ACETIC ACID Use and application,DIFLUOROMETHYLTHIO ACETIC ACID technical grade,usp/ep/jp grade.


Related News: The company’s pharmaceutical intermediate business is expected to maintain a growth rate of more than 30%.1,2,3-Tribromopropane manufacturer Active pharmaceutical ingredients or APIs can be defined as the chemicals used to manufacture pharmaceutical drugs.methyl 5-chloro-3-(methylsulfamoyl)thiophene-2-carboxylate supplier Active pharmaceutical ingredients or APIs can be defined as the chemicals used to manufacture pharmaceutical drugs.D-(+)-Methyl-alpha-(2-thienylethamino)(2-chlorophenyl)acetate hydrochloride vendor China’s pharmaceutical CMO market has recently maintained a growth rate of more than 10%. From the perspective of market structure, the average growth rate of clinical production is 9.5%, while the average growth rate of commercial production will reach 18.7%.The unit of the British drugmaker, which is challenging HIV drug market leader Gilead Sciences, said it will work with the FDA to determine the next steps for the new drug application.